Effects and Role of Multikinase Inhibitors in Thyroid Cancer.

Abstract

Thyroid cancer is the most common type of endocrine neoplasia. Differentiated thyroid carcinoma (DTC) represents 94% of all thyroid cancer types. Approximately 20% experience local recurrence and 10% distant metastasis. The recurrent DTC often becomes less differentiated, loses the iodine uptake capability and consequently loses the radioactive iodine treatment option. Under these circumstances survivability drops below 10% at 10 years. The treatment options for dedifferentiated thyroid cancers are extremely limited. This category sometimes referred to as poorly differentiated thyroid cancer (PDTC), is characterised by a missing response to radioiodine treatment and a remarkably reduced survivability. Therefore, new drugs have been developed to fill this gap in treatment.